Professor of Oncology and Internal Medicine, Roswell Park Cancer Institute and SUNY at Buffalo School of Medicine
Oncology
Dr. Philip E. McCarthy, MD
|
|
Give Review
Doctor Philip E. McCarthy, MD is an expert in the field of Oncology. He went to Tufts University School of Medicine. Tufts University School of Medicine has a rank of 49 in research and a 52 in primary care Doctor Philip E. McCarthy, MD is a published MD. He has 95 publications published. The most current publication "Housing Temperature-Induced Stress Is Suppressing Murine Graft-versus-Host Disease through 2-Adrenergic Receptor Signaling." He is registered with Medicare and accepts Medicare payments.
Publications
- Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.
- Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.
- Housing Temperature-Induced Stress Is Suppressing Murine Graft-versus-Host Disease through β2-Adrenergic Receptor Signaling.
- The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia.
- Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation.
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
- Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?
- Synchronous presentation of monoclonal gammopathy and Fabry nephropathy; diagnostic renal biopsy obviates initiation of myeloma therapy.
- Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
- Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant.
- Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples.
- Lenalidomide after stem-cell transplantation for multiple myeloma.
- Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
- Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy.
- Second transplant as a standard for multiple myeloma.
- Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.
- Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation.
- Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia.
- Toxic Tacrolimus Levels After Application of Topical Tacrolimus and Use of Occlusive Dressings in Two Bone Marrow Transplant Recipients with Cutaneous Graft-versus-Hos...
- Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation.
- The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
- Remestemcel-L for acute graft-versus-host disease therapy.
- Reprint of: Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation.
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
- Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
- Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.
- Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.
- Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.
- Back to the future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation.
- Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.
- Where Are We Going with Autologous Transplantation for Multiple Myeloma?
- Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and mye...
- Pilot study of patient and caregiver out-of-pocket costs of allogeneic hematopoietic cell transplantation.
- Effects of spleen status on early outcomes after hematopoietic cell transplantation.
- Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States.
- Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of...
- Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group Collaboration.
- Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients.
- Granzyme B-Mediated Damage of CD8+ T Cells Impairs Graft-versus-Tumor Effect.
- Multiple myeloma: future directions in autologous transplantation and novel agents.
- A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
- Progressive chronic lymphocytic leukemia after allogeneic hematopoietic cell transplantation.
- Elevating body temperature enhances hematopoiesis and neutrophil recovery after total body irradiation in an IL-1-, IL-17-, and G-CSF-dependent manner.
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-base...
- Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
- Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
- Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results.
- Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
- "Sowing dragon's teeth?" Myeloma and AML.
- Classifying Cytogenetics in Patients with AML in Complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study.
- The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Re...
- Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia.
- Effect of Obesity on Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
- One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood...
- Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies.
- Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?
- Self-determinism: alloBMT for AML.
- Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Resear...
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.
- Common genetic variants are associated with accelerated bone mineral density loss after hematopoietic cell transplantation.
- Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study.
- Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.
- Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations.
- Fatal diffuse alveolar hemorrhage associated with sirolimus after allogeneic hematopoietic cell transplantation.
- Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cel...
- A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow...
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
- Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.
- Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
- Outcome of transplantation for myelofibrosis.
- Reversible cardiotoxicity with tyrosine kinase inhibitors.
- A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
- Late infectious complications after cord blood stem cell transplantation.
- The effect of smoking on allogeneic transplant outcomes.
- Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.
- Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.
- Fatal hyperacute graft-versus-host disease following denileukin diftitox treatment for recurrent t cell lymphoma after allogeneic stem cell transplantation.
- Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy sta...
- Seeing what's out of sight: wireless capsule endoscopy's unique ability to visualize and accurately assess the severity of gastrointestinal graft-versus-host-disease.
- A comparison of measured creatinine clearance versus calculated glomerular filtration rate for assessment of renal function before autologous and allogeneic BMT.
- The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
- Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice.
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
- Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
- Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Cen...
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
- Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation.
- Comparison of twin and autologous transplants for multiple myeloma.
- Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies.
- Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
- Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
- Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National ...
- Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed ...
- High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.
Schools
Tufts University
St Elizabeths Hospital
Procedures Preformed
- Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer
- Hemorrhoidectomy or Excision of Anal Tags
Conditions Treated
- Anorectal Abscess
- Hemorrhoids
- Hidradenitis
- Hyperparathyroidism
- View All
Doctors Specialties
- General Surgery
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Yale-New Haven Hospital -
Tufts University School of Medicine
Hospital
-
Roswell Park Cancer Institute
Drug Facts
| NPI NUMBER | 1770574808 | |
| NPPES Provider LastName | MCCARTHY | |
| NPPES Provider FirstName | PHILIP | |
| NPPES Provider ZIPCode | 142630001 | |
| NPPES Provider State | NY | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 99.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1770574808 |
| Last Name Of The Provider | MCCARTHY |
| First Name Of The Provider | PHILIP |
| View All |
Similar Doctors
|
|
Dr. John E. Fattore, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott J. Banuelos, MD |
|
|
Dr. Frederick M. Gale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arthur H. Glasgow, MD
This Doctor is OpenDoctor Recommended.
|